Trial Profile
A Three Month Prospective Open Label Study Of Therapy With Fragmin(Registered) (Dalteparin Sodium Injection) In Children With Venous Thromboembolism With Or Without Malignancies
Status:
Completed
Phase of Trial:
Phase II
Latest Information Update: 12 Jul 2022
Price :
$35
*
At a glance
- Drugs Dalteparin sodium (Primary)
- Indications Deep vein thrombosis; Pulmonary embolism; Venous thromboembolism
- Focus Pharmacodynamics
- Sponsors Eisai Co Ltd; Pfizer
- 01 Aug 2022 Results published in the Pediatric Blood and Cancer
- 12 Aug 2020 Results (n=89) of population pharmacokinetics analysis from three clinical studies: FRAG-A001-201, Kids-DOTT and a retrospective chart study at Mayo clinic published in the Journal of Clinical Pharmacology
- 30 May 2019 This trial has been completed in Croatia, according to European Clinical Trials Database.